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Abstract
Background: The success and cost-effectiveness of bowel cancer screening depends on achieving and
maintaining high screening uptake rates. The involvement of GPs in screening has been found to improve patient
compliance. Therefore, the endorsement of screening by GPs may increase uptake rates amongst non-responders.
Methods/Design: A two-armed randomised controlled trial will evaluate the effectiveness of a GP endorsed
reminder in improving patient participation in the NHS Bowel Cancer Screening Programme (NHSBCSP). Up to 30
general practices in the West Midlands with a screening uptake rate of less than 50% will be recruited and patients
identified from the patient lists of these practices. Eligible patients will be those aged 60 to 74, who have
previously been invited to participate in bowel screening but who have been recorded by the Midlands and North
West Bowel Cancer Screening Hub as non-responders. Approximately 4,380 people will be randomised in equal
numbers to either the intervention (GP letter and duplicate FOBt kit) or control (no additional contact) arms of the
trial.
The primary outcome measure will be the difference in the uptake rate of FOBt screening for bowel cancer
between the intervention and control groups at 13 weeks after the GP endorsed reminder and duplicate FOBt kit
are sent. Secondary outcome measures will be subgroup analyses of uptake according to gender, age and
deprivation quartile, and the validation of methods for collecting GP, NHSBCSP and patient costs associated with
the intervention. Qualitative work (30 to 40 semi-structured interviews) will be undertaken with individuals in the
intervention arm who return a FOBt kit, to investigate the relative importance of the duplicate FOBt kit, reminder
to participate, and GP endorsement of that reminder in contributing to individuals’ decisions to participate in
screening.
Discussion: Implementing feasible, acceptable and cost-effective strategies to improve screening uptake amongst
non-responders to invitations to participate is fundamentally important for the success of screening programmes. If
this feasibility study demonstrates a significant increase in uptake of FOBt screening in individuals receiving the
intervention, a definitive, appropriately powered future trial will be designed.
Trial registration number: ISRCTN: ISRCTN86784060
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Colorectal cancer (CRC) is the third most common can-
cer, and second leading cause of cancer death in the
UK, with 35,000 diagnoses and 16,000 deaths per year
[1]. It incurs an annual expenditure of more than £300
million in surgical, adjuvant and palliative treatment [2]
which could be significantly reduced by earlier diagnosis
through bowel cancer screening. The five-year survival
rate for CRC is currently around 47% [3], lower than in
other European countries [4,5]. Despite improvements
in cancer survival over the past decade, the deprivation
gap in survival for many cancers, including CRC, has
been widening [6], and a key recommendation of the
Department of Health’s 2011 Cancer Reform Strategy is
the development and implementation of strategies to
facilitate earlier diagnosis of cancer, including the
improvement and expansion of screening [7].
Biennial bowel screening using the Faecal Occult
Blood test (FOBt) has been shown in randomised con-
trolled trials (RCTs) to have the potential to reduce
mortality from bowel cancer by 16% [8]. FOBt screening
in the average risk asymptomatic population can detect
bowel cancer at an earlier stage than would be the case
through symptomatic presentation, meaning that treat-
ment is more likely to be effective [9]. In addition to
improved survival, the benefits of earlier diagnosis
through screening include improved patient quality of
life and reduced NHS treatment costs [10]. However, if
these benefits are to be realised, high levels of screening
uptake and continued adherence over time must be
achieved and maintained in the eligible population.
In England, bowel cancer screening using FOBt was
introduced in 2006 and has now been rolled out nation-
ally, co-ordinated through the NHS Bowel Cancer
Screening Programme (NHSBCSP). The programme
aims to screen men and women aged between 60 and
74 every two years, using a guaiac faecal occult blood
test. Evaluations carried out when the programme was
in the pilot stage demonstrated relatively low rates of
uptake (58.5% and 52% in the first and second rounds
of screening respectively) [11,12].
Interventions to increase uptake are required, and in
particular, the development of feasible and acceptable
strategies to improve compliance with bowel cancer
screening amongst non-responders. Several studies have
investigated the role of various interventions in increas-
ing compliance with cancer screening [13]. Patient inter-
ventions have typically focused on the effectiveness of
invitations to screening in increasing uptake [14]; remin-
ders sent to those who fail to respond to invitations for
screening [15], and educational interventions to increase
knowledge about a given screening programme [16,17].
Interventions aimed at providers have focused on
reminders or prompts to general practitioners (GPs) to
encourage individuals to undergo screening [18], and
educational initiatives to maintain medical knowledge
and levels of training in relation to bowel cancer screen-
ing [19].
Intervention studies conducted to date have typically
failed to demonstrate significant improvements in com-
pliance, or have had a greater impact on some sub-
groups of the population than others [20], thus increas-
ing inequalities in screening uptake further. Many have
focused on opportunistic rather than population-based
screening [21], and much research has been undertaken
in the US, and as such may have limited applicability to
the UK context. This indicates a need to consider alter-
native strategies to increase the uptake of bowel cancer
screening in the asymptomatic population.
The involvement of GPs has been found to improve
patient compliance with bowel cancer screening
[19,21,22], and the uptake of FOBt is higher in groups
that are sent a reminder to participate [14,15]. Doctors
are typically cited as the most trusted profession in sur-
veys of the public [23], and healthcare professionals
(GPs in particular), are consistently rated as the primary
source of information that patients seek regarding health
and health services [24]. This existing research points to
the importance of health professionals in supporting
patients in making decisions about their healthcare, yet
this research has largely been conducted outside of the
UK, and no studies of interventions to increase the
uptake of bowel cancer screening have been conducted
since the introduction of the NHSBCSP in 2006.
Furthermore, non-responders to previous invitations to
participate in bowel screening have not been targeted as
a specific group in whom rates of screening uptake may
be increased. Despite GPs having minimal direct invol-
vement with bowel cancer screening in the programme
as currently designed, a potential strategy to improve
participation in the NHSBCSP is a reminder from the
GP, sent to non-responders to an initial invitation to
participate in bowel screening. This approach has been
found to be successful in increasing attendance for
breast screening [25], yet the transferability of these
findings to screening for bowel cancer is unknown, as it
is aimed at a different target population. Furthermore,
the factors contributing to an individual’s decision to
participate in bowel screening are likely to differ from
those affecting decisions to participate in other cancer
screening programmes.
Study aim
The main aim of this feasibility study is to evaluate the
effectiveness of a primary care based intervention (GP
endorsed reminder and duplicate FOBt kit) on
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amongst non-responders to a previous invitation to
participate.
Methods/design
This feasibility study comprises a two-armed rando-
mised controlled trial (n = 2190 in each arm) to evaluate
the effectiveness of GP endorsement and a duplicate
FOBt kit (compared with no additional contact) on
improving the patient uptake of FOBt screening, and an
embedded qualitative study in which semi-structured
interviews will be undertaken with 30 to 40 individuals
in the intervention arm of the trial who return their
FOBt kit following the intervention.
The NHS Bowel Cancer Screening Programme
Bowel cancer screening in England is organised through
five regional screening Hubs which invite individuals to
participate in screening - each regional Hub working
with up to 20 local screening centres. The Hub sends an
invitation and a leaflet about bowel cancer and the
screening programme to all eligible patients registered
w i t haG Pi nt h e i rr e g i o n ,f o l l o w e db yaF O B tk i t
around eight days later. Individuals are directed to com-
plete the FOBt at home and return it to the screening
centre for analysis. Those whose FOBt shows a positive
result are then invited for further investigation through
colonoscopy. If the Hub does not receive a completed
kit within four weeks of sending it, a reminder is sent.
After 13 weeks, the ‘screening episode’ is closed, and
those who have not returned their kit are recorded as
non-responders on the Hub database. In the Midlands,
bowel cancer screening is co-ordinated by the Midlands
and North West Bowel Cancer Screening Hub, based in
Rugby.
Study population
The study population will be adults aged between 60
and 74, on the patient list of a general practice where
the bowel screening uptake rate is < 50%, who were
invited to participate in the most recent round of bowel
screening but who have not returned their FOBt within
the 13 week ‘screening episode’ recorded by the Mid-
lands and North West Bowel Cancer Screening Hub.
Participant selection
Participant selection will be undertaken in two stages.
First, the Midlands and North West Bowel Cancer
Screening Hub will identify general practices in the
West Midlands where the uptake of bowel cancer
screening is lower than 50%. The contact details of
these practices will be obtained via the MidReC (Mid-
lands Research Practices Consortium) database, and all
eligible practices will be contacted by the research team
at the University of Birmingham and invited to partici-
pate, with general practice recruitment continuing until
a total of up to 30 practices have been recruited. Once
practices have been recruited, the Hub will identify all
eligible screening non-responders aged 60 to 74 at each
participating practice. Non-responders will be defined as
those who have not responded to either the initial invi-
tation to screening, or the 4-week reminder, within a
period of 13 weeks after being invited.
Inclusion criteria
Individuals aged between 60 and 74 years old, on the
patient list at a general practice with a bowel cancer
screening uptake lower than 50%, who have been
recorded by the screening Hub as a screening non-
responder no less than one month and no more than
seven months previously.
Exclusion criteria
Patients will be excluded from the trial if:
1. They have undergone an investigation (e.g. colo-
noscopy) within the past two years and/or are cur-
rently under surveillance following a previous
colorectal abnormality
2. They have moved outside of the 60 to 74 year age
range for screening in the time since their initial 13
week screening episode
3. They have contacted the Hub requesting not to be
sent any information about bowel cancer screening,
or FOBt kits
Randomisation
For each participating general practice, the Hub will
separate the names and details of the screening non-
responders, determine any exclusions, and send anon-
ymised details for eligible trial participants (each indivi-
dual assigned a unique identifier) to the UK Clinical
Research Network (UKCRN) accredited Primary Care
Clinical Research and Trials Unit (PC-CRTU) at the
University of Birmingham for patients to be randomised.
Randomisation will be carried out using a computer
generated randomisation algorithm, with patients rando-
mised in equal numbers to the intervention or control
arms of the study (n = 4,380). Block randomisation at
the general practice level will ensure a balance of the
two arms within each participating practice.
Intervention Group
Patients in the intervention arm of the trial will receive
a personalised letter recommending bowel cancer
screening signed by their GP and a duplicate Hema-
screen FOBt kit. The letter and duplicate kit will be sent
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The same letter template will be used for all participat-
ing GP practices, but each GP will be able to modify the
wording of the letter if there are particular issues that
they would like to highlight to their patients. Patients
recruited to the trial will be logged by the Hub database
via a reopening of the individual’s screening record,
which would have been closed initially after the 13 week
screening window that defined that individual as a non-
responder.
Control Group
Patients randomised to the control arm of the trial will
receive no additional contact (current standard practice).
Outcome measures
T h ep r i m a r yo u t c o m em e a s u r ew i l lb et h ed i f f e r e n c ei n
the uptake rate of FOBt screening for bowel cancer (i.e.
the proportion of individuals who return a FOBt kit to
the screening Hub) between the intervention and con-
trol group after 13 weeks.
Secondary outcome measures will include sub-group
analysis of screening uptake rates following the interven-
tion, according to age, gender and deprivation quartile,
and the development and validation of methods and pro-
formas for collecting information on GP, NHSBCSP and
patient costs associated with the intervention. Such costs
are anticipated to include the cost to the Hub of sending
GP reminders to screening non-responders; costs asso-
ciated with staff workload in sending reminders; time
costs for participants, and costs to primary care if the
intervention results in an increased number of patients
contacting their GP to discuss bowel cancer screening.
Outcome collection
13 weeks after initial contac t( i . e .w h e na ni n d i v i d u a l ’s
screening episode is due to close), the Hub will log the
number of FOBt kits returned by individuals in the
intervention and control arms of the trial, and return
anonymised lists of patients, denoted by a unique identi-
fication number, to the University of Birmingham for
analysis. The member of hub staff collecting the out-
comes data will be blinded to randomisation group to
avoid bias.
Participating general practices will be asked to record
prospectively all patient consultations about bowel can-
cer screening during the trial. In order to determine the
relative effectiveness of retrieving information on con-
sultations where screening was discussed from routine
GP records (i.e. compared to prospective recording by
the GP), a retrospective analysis of routinely collected
GP records will be carried out in two of the participat-
ing practices. When the trial has ended, the screening
Hub will produce a list of all patients who had been
randomised within these two practices. Practice staff
will be asked to inform the research team of the number
of consultations relating to bowel cancer screening that
have been carried out for these patients.
Sample size
General practices with a screening uptake rate of less
than 50% will be purposively recruited. Assuming an
average GP list size of 2,750 (information derived from
the MidReC general practice database), with 11.8% of
the population aged between 60 and 74 years old [26],
and a bowel cancer screening participation rate of 45%,
there will be 146 eligible individuals per practice (Figure
1). Thirty practices will provide 4,380 people for rando-
misation to the intervention or control arms of the trial.
Assuming a screening uptake rate of 3.2% in the control
arm (Midlands and North West Screening Hub recorded
rate of delayed FOBt return amongst previous non-
responders), a comparison of proportions test shows
that a sample size of 934 in both the intervention and
control groups is required in order to demonstrate a
doubling of the uptake rate (from 3.2% to 6.4% or more)
with 90% power at the 5% significance level. The larger
number of patients (n = 2,190 in each group) has been
chosen in order to enable sub-group analyses to be
undertaken, and to account for any effects of nesting of
patients within general practices should interim analyses
demonstrate that such nesting is occurring.
Qualitative study
Previous research exploring the patient factors asso-
ciated with bowel cancer screening participation has
provided limited information about significant sociode-
mographic and psychosocial factors, but the relative
Figure 1 Study schematic.
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yielded conflicting information [27]. Multi-factorial
approaches, combining behavioural and educational
strategies with healthcare interventions such as GP
endorsed screening reminders are likely to be an impor-
tant means of addressing the low uptake of CRC screen-
ing in the long term. Qualitative methodologies are a
highly appropriate means of eliciting information about
beliefs, attitudes and knowledge, and the ways that indi-
viduals justify their decision-making, particularly where
the factors of concern may be unclear. Undertaking an
embedded qualitative study will allow us to begin to
understand the relative influence on individual decision-
making of the three components of this intervention -
receiving a reminder, receiving a duplicate FOBt kit, and
endorsement of screening by an individual’s GP.
Population
Approximately 30 to 40 individuals in the intervention
arm of the study, who return their FOBt kit after receiv-
ing a reminder from their GP, will be recruited to parti-
cipate in a semi-structured interview to investigate their
reasons for returning the kit.
Recruitment
The Hub will send a letter inviting participation in a
semi-structured interview to all individuals who have
returned a FOBt kit following the intervention. A reply
slip, on which patients can indicate their willingness to
be interviewed, will be enclosed with the invitation let-
ter, which will be returned to the University of Birming-
ham so that an interview can be arranged. All non-
responders to an invitation to participate in an interview
will receive one reminder from the screening Hub.
Recruitment to the qualitative study will continue until
data saturation has been reached, or until 30 to 40
interviews have been undertaken.
Feasibility
If the GP endorsed reminder is successful, we expect
around 140 FOBt kits to be returned by patients rando-
mised to the intervention arm of the trial. We aim to
invite all patients in the trial intervention arm who
returned a FOBt kit for interview, and conservatively
estimate a response rate of 25% based on recruitment
levels achieved in previous qualitative studies associated
with bowel cancer screening uptake (Clements et al.
personal communication). This would equate to
approximately 35 individuals willing to participate in the
qualitative phase.
Data collection
Interviews will take place either in a location of the par-
ticipant’s choice, or by telephone, and will be conducted
by an experienced qualitative researcher. The topic
guide will focus on attitudes and beliefs about bowel
cancer screening, reasons for previous participation and/
or non-participation in screening, and reasons for
participation following the trial intervention. All inter-
views will be digitally audio-recorded and transcribed,
and each will last approximately 60 minutes.
Analysis
Trial data will be analysed on an intention to treat basis.
The primary outcome measure (screening uptake in the
intervention and control arms of the trial) will be ana-
lysed using a non-linear mixed logit model for dichoto-
mous outcomes, accounting for practices as random
effects. Secondary analyses will include comparison of
screening uptake rates by sub-group on the basis of
patient characteristics (age, gender, deprivation);
whether or not the GP letter template was modified by
a participating practice; previous bowel cancer screening
behaviour, and according to the time period between an
individual’s first screening episode and the intervention.
A multivariable prognostic model will be developed,
incorporating interaction terms between factors. Deci-
sion tree analysis will also be undertaken, and the find-
ings from these complementary analytical approaches
will be cross-validated in order to identify factors pre-
dictive of delayed participation in the NHSBCSP [28].
Evaluating the potential influence of previous bowel
screening behaviour on screening uptake rates within
the feasibility work will inform the design of any future
definitive trial with regard to establishing the need to
stratify trial participants according to past screening
behaviour prior to randomisation.
The characteristics of participating and non-participat-
ing general practices (i.e. those who were invited but
who declined to participate) will be compared, using
information derived from the MidReC general practice
database in order to ascertain practice compliance rates
and to investigate potential selection bias and confoun-
ders at the practice level. Comparisons will be made
with regard to practice list size and other GP/practice-
related factors (e.g. whether a practice is single-handed
or has multiple partners; the socioeconomic deprivation
profile of the practice catchment area, and the propor-
tion of ethnic minority patients within the geographical
area covered by the practice). These analyses will inform
the design and methodology of any future definitive trial
of the intervention.
Analysis within the qualitative study will be carried
out by reading the interview transcripts and identifying
emerging themes and categories. Each transcript will be
independently analysed by two experienced qualitative
researchers using thematic analysis. Themes arising
from each interview will be compared in order to detect
similarities and differences, and a constant comparative
approach will be used, so that important themes arising
from earlier interviews can be incorporated into a flex-
ible topic guide for exploration in subsequent interviews.
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All activities undertaken by the Midlands and North
West Bowel Cancer Screening Hub are covered by
National Information Governance Board (NIGB, for-
merly the Patient Information Advisory Group, PIAG)
approvals with regard to the handling of patient-identifi-
able data (Ref: PIAG 1-08(a)/2003).
No patient identifiable data will be seen by researchers
outside of the screening Hub prior to consent for parti-
cipation in the qualitative phase of the study. Any
patient information (name, address) supplied by patients
when returning a reply slip to the University of Birming-
ham indicating their willingness to participate in a semi-
structured interview will be managed by the research
staff with established procedures to ensure the confiden-
tiality of those data and in accordance with applicable
national and/or local regulations on personal data
protection.
Data monitoring
Although adverse events are not anticipated as part of
this feasibility trial, it is possible that the intervention
may increase the number of patients contacting the
screening Hub in order to opt out of participation in
any future rounds of bowel cancer screening. The Hub
will inform the research team, at the end of the trial, of
those individuals (anonymised, unique identifier only)
who had contacted them to decline bowel cancer
screening subsequent to receipt of the intervention.
An independent Data Monitoring Committee (DMC)
will be formed to oversee the conduct of the trial, and
will meet at regular intervals during the study. The
DMC will comprise a statistician, a clinician, and a Spe-
cialist Screening Practitioner (SSP), and will evaluate
interim outcomes and analyses to determine whether
the study should be stopped for any reason.
Ethical considerations
Ethical approvals have been obtained from South Bir-
mingham Research Ethics Committee (Ref: 11/WM/
0086), and R&D approvals have been obtained from
University Hospitals Coventry and Warwickshire NHS
Trust, Coventry Teaching Primary Care Trust and Bir-
mingham and the Black Country RM&G Consortium
Trusts (CSP Ref: 63560).
Consent to participate
Patients will be randomised without seeking consent.
This approach is being taken to avoid the likely bias in
screening uptake subsequent to the intervention that
would result if participants were made aware of their
involvement in the research study. Seeking consent from
individuals identified as non-responders by the Hub
would itself be an intervention; it would be impossible
to ascertain whether any difference in uptake between
the control and intervention arms was due to screening
participation being prompted by an approach seeking
consent for inclusion within the study, or because of the
effect of the GP endorsed reminder and duplicate FOBt
kit.
Written informed consent will be obtained from all
participants in the qualitative phase of the study prior to
interview.
Discussion
There is a lack of evidence to support the implementa-
tion of effective interventions to reduce the burden of
CRC by reducing delays in diagnosis or improving parti-
cipation in screening. It is estimated that there would be
20,000 fewer deaths over the next 20 years if bowel can-
cer screening had an uptake of 60% [29]. The success
and cost-effectiveness of the NHSBCSP depends on the
achievement and maintenance of high screening uptake
rates in the target population, and the development of
feasible, acceptable and cost-effective strategies to
improve compliance with bowel cancer screening offers
the opportunity to improve programme delivery and to
target population sub-groups who currently underuse
the service.
If the intervention proves effective in the feasibility
work, we envisage undertaking a definitive trial, which
will be designed and powered based on the findings of
the feasibility study. It is envisaged that the definitive
trial may compare Hub and GP endorsement of bowel
screening, with and without the inclusion of a duplicate
FOBt, to determine the relative importance of different
components of the intervention. It would also establish
the cost-effectiveness of the intervention for different
sub-groups, and assess the suitability of the intervention
being rolled out nationally within the NHSBCSP.
Trial Status
At the time of manuscript submission, recruitment to
this trial had not yet begun.
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